KC02 |
Catalog No.GC13023
One-Click Copy Product Info
|
Structural analog and inactive form of KC01
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1646795-60-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
KC02 is a structural analog of KC01 and inactive form of KC01.
The synthesis of KC02 consistently yielded a 4:1 mixture of Z/E isomers, which proved difficult to chromatographically separate. By competitive gel-based ABPP assys, KC02 inhibited ABHD16A (human and mouse) with IC50 value of >10μM, while KC01 is in range of nM. By PS substrate assays, KC02 inhibited human ABHD16A with IC50 value of > 10μM, while KC01 is in range of nM.
Most of these enzymes were also inhibited by the control probe KC02, with the exception of two partial off-targets, ABHD3 and ABHD13. KC02 also inhibited ABHD11 (94%) and LYPLA1 (63%) but did not substantially inhibit ABHD16A (<30%). In situ treatment with KC01 (1μM, 4 h) but not KC02 (1μM, 4 h) blocked the PS lipase activity of membrane fractions from COLO205, K562 and MCF7 cell lines. KC01 and KC02 constitute a suitable pair of active and inactive (control) probes to investigate the function of ABHD16A in cellular systems. Treatment with KC01 but not KC02 (1μM, 4 h) substantially lowered secreted lyso-PSs of the ABHD12-null LCL. All LCLs also showed decreased cellular lyso-PSs following treatment with KC01 but not KC02. KC01 but not KC02 elevated PS lipase activity and reduced in lyso-PS lipase activity in LPS-stimulated macrophages. The LPS-induced increases in lyso-PS and cytokine secretion were both blocked by pretreatment of Abhd12−/− macrophages with KC01 (1μM, 4 h) but not KC02 (1μM, 4 h).
In COLO205 cells, 1μM KC01 but not KC02 showed substantial reductions in the levels of all detected cellular lyso-PSs compared to DMSO-treated control cells. The levels of secreted lyso-PSs (18:1 and 18:0) were also decreased in COLO205 cells treated with KC01 compared to those in KC02- or DMSO-treated cells (4-h treatments of cells in serum-free medium), whereas levels of other secreted lipids (lyso-PCs, lyso-PEs and MAGs) were unchanged across these treatment groups.
KC01, but not KC02, inhibited the PS lipase activity of brain membrane lysates from 2-month-old Abhd12+/+ and Abhd12−/− mice.
Reference:
1.Kamat SS, Camara K2, Parsons WH et al. Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay. Nat Chem Biol. 2015 Feb;11(2):164-71.
| Cas No. | 1646795-60-9 | SDF | |
| Chemical Name | 6-(2-oxo-4-tridecyloxetan-3-yl)hexanamide | ||
| Canonical SMILES | CCCCCCCCCCCCCC1OC(C1CCCCCC(N)=O)=O | ||
| Formula | C22H41NO3 | M.Wt | 367.57 |
| Solubility | DMF: 5 mg/ml,DMSO: 5 mg/ml,Ethanol: 16 mg/ml,Ethanol:PBS(pH 7.2) (1:5): 0.5 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7206 mL | 13.6029 mL | 27.2057 mL |
| 5 mM | 544.1 μL | 2.7206 mL | 5.4411 mL |
| 10 mM | 272.1 μL | 1.3603 mL | 2.7206 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 13 reference(s) in Google Scholar.)